Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK2D | Q13557 | 5/20 | 0.53 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.52 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 3/20 | 0.50 |
| ▸ | SYK | P43405 | 7/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.48 |
| ▸ | CCND3 | P30281 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34464796 | 0.91 | SYK (0.50) | CAMK2DJAK2SYKCDK2CDK1 | |
| SCHEMBL34464820 | 0.91 | JAK2 (0.54) | CAMK2DJAK2SYKCDK2CDK1 | |
| SCHEMBL34464794 | 0.89 | JAK2 (0.56) | CAMK2DGSK3BMAPK8PIK3CGCAMKK2 | |
| Formic Acid SCHEMBL34464810 | 0.88 | JAK2 (0.51) | CAMK2DJAK2SYKCDK2CDK1 | |
| SCHEMBL34464824 | 0.85 | CAMK2D (0.48) | CAMK2DGSK3BMAPK8PIK3CGCAMKK2 | |
| SCHEMBL34464826 | 0.83 | ABL1 (0.61) | CAMK2DGSK3BMAPK8PIK3CGCAMKK2 | |
| SCHEMBL34464767 | 0.82 | CAMK2D (0.55) | CAMK2DGSK3BMAPK8PIK3CGCAMKK2 | |
| SCHEMBL34464745 | 0.81 | JAK2 (0.56) | CAMK2DMAPK8JAK2SYKCDK2 | |
| SCHEMBL34464802 | 0.81 | JAK2 (0.53) | CAMK2DJAK2CDK2CDK1JAK3 | |
| SCHEMBL34464746 | 0.80 | JAK2 (0.67) | CAMK2DMAPK8JAK2SYKCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109690-A1 | HDAC6 INHIBITORS AND METHOD OF THEIR USE | BAERENKRAFT THERAPEUTICS LLC (US) | 2026-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109690-A1 | HDAC6 INHIBITORS AND METHOD OF THEIR USE | HDAC6, HDAC3, HDAC1 | CAMK2D 378/4885GSK3B 285/4885MAPK8 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.